{
    "topic": "Heparin/Warfarin Anticoagulation Safety",
    "category": "priorityAction",
    "difficulty": 5,
    "ngnType": "Bowtie",
    "stem": "The nurse is caring for a client receiving both heparin and warfarin. Review the client's information and determine the priority action, likely condition, and two (2) actions to take.",
    "itemContext": {
        "SBAR": "14:00\nS: The client is a 72-year-old male, admitted for atrial fibrillation, started on heparin and warfarin 3 days ago.\nB: History of hypertension, hyperlipidemia, and recent knee replacement. Medications include metoprolol, atorvastatin, heparin 5000 units SQ q12h, and warfarin 5mg PO daily.\nA: Currently, the client reports nosebleeds and new onset hematuria. INR is 6.2. aPTT is 90 seconds. Hemoglobin is 10 g/dL (100 g/L) and hematocrit is 30%. The client is alert and oriented, but anxious. Vital signs: BP 160/90 mmHg, HR 90 bpm, RR 20, SpO2 96% on room air. Next warfarin dose is due at 20:00.\nR: I am concerned about potential bleeding complications due to supratherapeutic INR and aPTT levels. Requesting orders for stat dose of Vitamin K, hold warfarin, and further evaluation.",
        "Labs": "INR: 6.2\naPTT: 90 seconds\nHemoglobin: 10 g/dL (100 g/L)\nHematocrit: 30%",
        "Vitals": "BP: 160/90 mmHg\nHR: 90 bpm\nRR: 20\nSpO2: 96% on room air",
        "MAR": "Metoprolol PO daily\nAtorvastatin PO daily\nHeparin 5000 units SQ q12h\nWarfarin 5mg PO daily (next dose due at 20:00)",
        "Radiology": "N/A"
    },
    "options": [
        {
            "0": "Assess the client's neurological status.",
            "1": "Administer the next scheduled dose of heparin.",
            "2": "Prepare to administer protamine sulfate IV.",
            "3": "Hold the next scheduled dose of warfarin.",
            "4": "Increase the rate of the client's IV fluids.",
            "id": "priorityAction",
            "text": "Assess the client's neurological status.,Administer the next scheduled dose of heparin.,Prepare to administer protamine sulfate IV.,Hold the next scheduled dose of warfarin.,Increase the rate of the client's IV fluids."
        },
        {
            "0": "Heparin-induced thrombocytopenia (HIT)",
            "1": "Pulmonary embolism",
            "2": "Warfarin-induced skin necrosis",
            "3": "Adverse reaction to metoprolol",
            "4": "Anticoagulant-induced hemorrhage",
            "id": "condition",
            "text": "Heparin-induced thrombocytopenia (HIT),Pulmonary embolism,Warfarin-induced skin necrosis,Adverse reaction to metoprolol,Anticoagulant-induced hemorrhage"
        },
        {
            "0": "Administer vitamin K intravenously.",
            "1": "Administer fresh frozen plasma (FFP).",
            "2": "Prepare for a blood transfusion.",
            "3": "Elevate the head of the bed.",
            "4": "Apply pressure to the site of bleeding.",
            "id": "action1",
            "text": "Administer vitamin K intravenously.,Administer fresh frozen plasma (FFP).,Prepare for a blood transfusion.,Elevate the head of the bed.,Apply pressure to the site of bleeding."
        },
        {
            "0": "Monitor the client's urine output.",
            "1": "Monitor the client's blood pressure.",
            "2": "Assess the client's pain level.",
            "3": "Notify the health care provider.",
            "4": "Document the findings in the electronic health record.",
            "id": "action2",
            "text": "Monitor the client's urine output.,Monitor the client's blood pressure.,Assess the client's pain level.,Notify the health care provider.,Document the findings in the electronic health record."
        }
    ],
    "response": {
        "priorityAction": "Hold the next scheduled dose of warfarin.",
        "condition": "Anticoagulant-induced hemorrhage",
        "action1": "Administer vitamin K intravenously.",
        "action2": "Notify the health care provider."
    },
    "rationale": {
        "priorityAction": "The client's INR of 6.2 indicates supratherapeutic anticoagulation with warfarin, significantly increasing the risk of bleeding. The priority action is to hold the next dose of warfarin to prevent further elevation of the INR and reduce the risk of hemorrhage. Assessing neurological status is important but secondary to immediately addressing the anticoagulation issue. Protamine sulfate is the antidote for heparin, not warfarin. Increasing IV fluids is not directly related to the anticoagulation issue.",
        "condition": "The client's elevated INR and aPTT, along with reports of nosebleeds and hematuria, strongly suggest anticoagulant-induced hemorrhage. Warfarin and heparin, while effective anticoagulants, increase the risk of bleeding when not properly monitored or when the dosage is too high. The client's presentation aligns with this complication. Heparin-induced thrombocytopenia (HIT) is characterized by a drop in platelet count, which is not indicated in this scenario. Pulmonary embolism is possible but not directly indicated by the provided data. Skin necrosis is a rare complication of warfarin, usually occurring early in therapy, and is not indicated by the presenting symptoms. Metoprolol is unlikely to cause these symptoms.",
        "action1": "Vitamin K is the antidote for warfarin and should be administered to reverse the effects of the anticoagulant and reduce the INR. Fresh frozen plasma (FFP) can also be used to provide clotting factors, but Vitamin K is the more specific initial intervention. A blood transfusion may be necessary if the client's hemoglobin continues to drop or if bleeding is severe, but it's not the immediate priority. Elevating the head of the bed and applying pressure to the bleeding site are supportive measures but do not address the underlying cause of the bleeding.",
        "action2": "The healthcare provider must be notified of the client's condition and the interventions implemented. The provider can then order further diagnostic tests, adjustments to the medication regimen, or additional treatments as needed. Monitoring urine output, blood pressure, and pain levels, and documenting findings are all essential nursing actions, but notifying the provider is critical for collaborative management of the client's condition.",
        "correct": "The client presents with signs of bleeding (nosebleeds, hematuria) and significantly elevated INR and aPTT levels, indicating an increased risk of hemorrhage due to warfarin and heparin. The priority is to hold the next dose of warfarin to prevent further elevation of the INR. Vitamin K, the antidote for warfarin, should be administered intravenously to reverse the effects of the anticoagulant. The healthcare provider should be notified immediately to evaluate the client and adjust the medication regimen. \n\nClinical Pearl: Always prioritize actions that directly address the immediate life-threatening risk, such as hemorrhage. In anticoagulation management, this includes holding the medication and administering the appropriate antidote.\n\nQuestion Trap: Many students may focus on the heparin first, but the more critical lab value is the INR, indicating warfarin toxicity. Students might also confuse the reversal agents for heparin and warfarin.\n\nMnemonic: When INR is high, think 'K' for Vitamin K, and 'Hold' the warfarin nigh.",
        "questionTrap": {
            "trap": "Common Pitfall",
            "howToOvercome": "Many students may focus on the heparin first, but the more critical lab value is the INR, indicating warfarin toxicity. Students might also confuse the reversal agents for heparin and warfarin."
        },
        "mnemonic": {
            "title": "HINT",
            "expansion": "When INR is high, think 'K' for Vitamin K, and 'Hold' the warfarin nigh."
        }
    },
    "scoring": {
        "method": "polytomous",
        "maxPoints": 1
    },
    "pedagogy": {
        "bloomLevel": "apply",
        "cjmmStep": "analyzeCues",
        "nclexCategory": "Physiological Adaptation",
        "topicTags": [
            "Uncategorized"
        ],
        "difficulty": 5
    },
    "id": "NCLEX-2026-MISSION-500-14-1771956842176"
}